ORTHO CYCLEN-21 Drug Patent Profile
✉ Email this page to a colleague
When do Ortho Cyclen-21 patents expire, and when can generic versions of Ortho Cyclen-21 launch?
Ortho Cyclen-21 is a drug marketed by Janssen Pharms and is included in one NDA.
The generic ingredient in ORTHO CYCLEN-21 is ethinyl estradiol; norgestimate. There are twenty-six drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norgestimate profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ORTHO CYCLEN-21?
- What are the global sales for ORTHO CYCLEN-21?
- What is Average Wholesale Price for ORTHO CYCLEN-21?
Summary for ORTHO CYCLEN-21
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 6 |
| Clinical Trials: | 20 |
| Patent Applications: | 8 |
| DailyMed Link: | ORTHO CYCLEN-21 at DailyMed |
Recent Clinical Trials for ORTHO CYCLEN-21
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Gilead Sciences | Phase 1 |
| Lexicon Pharmaceuticals | Phase 1 |
| Aegerion Pharmaceuticals, Inc. | Phase 1 |
US Patents and Regulatory Information for ORTHO CYCLEN-21
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Janssen Pharms | ORTHO CYCLEN-21 | ethinyl estradiol; norgestimate | TABLET;ORAL-21 | 019653-001 | Dec 29, 1989 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
